TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provi…
USD64.51-0.08%vs prev. close
Performance
1W
+7.83%
1M
+18.65%
3M
+32.36%
1Y
+108.37%
YTD
+116.40%
Valuation
P/E
96.3
EPS TTM
0.67
Dividend yield
—
Size and risk
Market cap
$9.8B
Beta
1.81
Price history
TGTX price
USD
Total returnEventsVs index
Loading…
Next earnings
Report date
EPS estimate
Revenue estimate
Peer comparison
TG Therapeutics
TGTX
Biotechnology
Mkt cap (USD bn)
9.8
P/E
96.3
Div yld
—
1W
+7.8%
1M
+18.6%
3M
+32.4%
6M
+63.3%
1Y
+108.4%
YTD
+116.4%
Company
Ticker
Industry
Mkt cap (USD bn)
P/E
Div yld
1W
1M
3M
6M
1Y
YTD
TG Therapeutics
TGTX
Biotechnology
9.8
96.3
—
+7.8%
+18.6%
+32.4%
+63.3%
+108.4%
+116.4%
Subscribe to Equity Analytics to compare TGTX with its closest peers
Sector-matched peer set with side-by-side valuation, dividend and performance over every window.